

HEMO-STOP® TABS

Tablet Oral

Anti-hemorrhagic of Dual Effect Hemostatic Platelet with Antifibrinolytic Factor



Formulation

H

Each tablet contains: Etamsylate 250 mg, Tranexamic acid 250 mg, excipients q.s.ad 1 tablet

Indications

Coadjuvant in the treatment and control of hemorrhages. Control of hemostasis in traumatic, surgical, pathological processes and obstetric manipulations. Pre, trans and post-surgical haemorrhagic prophylaxis. In accidental traumatology, control of dysfunctional uterine bleeding, coadjuvant in the treatment of coagulation disorders and prevention of small blood vessel hemorrhages, hematuria (not of renal origin), melena, hematemesis, epistaxis, parvovirosis, auriculohematomas, caudotomy, auriculotomy, metrograms, elitrorragias, oncotomies, NSAID poisoning, gastric and duodenal ulcer perforation, traumatic peritonitis, ecchymosis, purpura, post-surgical hemorrhages, among others. Control of hyperfibrinolysis associated with infection by Angiostrongylus vasorum.

Dosage and Administration

Oral Route . At a rate of 10 to 12.5 mg of ethamsilate and 10 to 12.5 mg of tranexamic acid / kg of body weight (1/2 tablet per 10 to 12.5 kg) every 6-8 hours until the desired effect is achieved. Administer for 1 to 5 days or until bleeding is controlled. In surgery: Preoperative: 1 hour before surgery. Postoperative: every 6-8 hours while the risk of bleeding persists.

Commercial Presentation

Box x 30 tablets,

SENASA Registry

SENASA Peru: F.C2.31.I.0001

Este contenido es una referencia informativa y no debe ser considerado como recomendaciones de uso.